Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Natco PharmaNSE:NATCOPHARM -1.38%89 PB Ratio is 1.78 as of Aug. 01, 2026, which is 42% below its 10-year median of 3.06. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 89/100 and a GF Value™ of ₹925.32 (Fairly Valued). The stock has 2 warning signs investors should review. Among 921 Drug Manufacturers companies, Natco Pharma ranks better than 51.47% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-01), Natco Pharma's share price is ₹917.00. Natco Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was ₹514.83. Hence, Natco Pharma's PB Ratio of today is 1.78.
Good Sign:
Natco Pharma Ltd stock PB Ratio (=1.79) is close to 10-year low of 1.66.
The historical rank and industry rank for Natco Pharma's PB Ratio or its related term are showing as below:
NSE:NATCOPHARM'
s PB Ratio Range Over the Past 10 Years
Min: 1.66 Med: 3.06 Max: 11.33
Current: 1.79
During the past 13 years, Natco Pharma's highest PB Ratio was 11.33. The lowest was 1.66. And the median was 3.06.
NSE:NATCOPHARM's PB Ratio is ranked better than 51.47% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs NSE:NATCOPHARM: 1.79
During the past 12 months, Natco Pharma's average Book Value Per Share Growth Rate was 21.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 24.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 19.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 18.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Natco Pharma was 48.50% per year. The lowest was 7.00% per year. And the median was 19.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Natco Pharma PB Ratio Related Terms
Natco Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Natco Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natco Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Natco Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Natco Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Natco Pharma (NSE:NATCOPHARM) has a PB Ratio of 1.78 as of Aug. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Natco Pharma and its competitors. This is 42% below median its historical median of 3.06. Over the past decade, Natco Pharma's PB Ratio has ranged from 1.66 to 11.33. According to the industry distribution chart, Natco Pharma ranks #447 out of 921 companies in the Drug Manufacturers industry, placing it in the top 48.5%.
Is Natco Pharma's PB Ratio too high?
Natco Pharma's current PB Ratio of 1.78 is 42% below median its 10-year median of 3.06. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 11.33. The Drug Manufacturers industry median PB Ratio is 1.88. Natco Pharma's value of 1.78 is 5.3% below this industry median. Based on the distribution chart, Natco Pharma ranks #447 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #447 out of 921 companies for PB Ratio. This puts Natco Pharma in the upper half of its industry. The industry median PB Ratio is 1.88. Natco Pharma's value of 1.78 is 5.3% below this benchmark. Historically, Natco Pharma's own PB Ratio has ranged from 1.66 to 11.33 over the past decade. While the company's 10-year median is 3.06 vs. the industry median of 1.88, Natco Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natco Pharma's current PB Ratio of 1.78 is 5.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current PB Ratio is 1.78, which is 42% below median its own 10-year median of 3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹925.32, compared to a current price of ₹917.00 — trading 0.9% below its estimated fair value. The current PB Ratio is 1.78, which is 42% below median its 10-year median of 3.06 and 5.3% below the Drug Manufacturers industry median of 1.88. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current PB Ratio is 1.78 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued.
The current stock price of ₹917.00 is trading 0.9% below its estimated GF Value™ of ₹925.32.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
PB Ratio: 1.78 (42% below median its 10-year median of 3.06)
GF Value™: ₹925.32 vs. price of ₹917.00 (0.9% below fair value)
Industry Position: 5.3% below the Drug Manufacturers median (#447 of 921)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score
Get the complete analysis for NSE:NATCOPHARM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
